BridgeBio Pharma, Inc.
BBIONasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $502.1M | $221.9M | $9.3M | $77.6M | $69.7M | $8.2M |
| Operating income | −$523.4M | −$593.0M | −$607.4M | −$512.2M | −$576.6M | −$474.5M |
| Net income | −$732.9M | −$543.3M | −$653.3M | −$484.7M | −$586.5M | −$505.5M |
| Total assets | $936.0M | $919.3M | $546.4M | $623.0M | $1.01B | $703.6M |
| Total liabilities | $3.01B | $2.38B | $1.89B | $1.87B | $1.88B | $595.7M |
| Equity | −$2.09B | −$1.47B | −$1.35B | −$1.25B | −$870.4M | $57.9M |
| EPS (diluted) | $-3.78 | $-2.88 | $-3.95 | $-3.26 | $-3.90 | $-3.80 |
| Shares out. | 190.2M | 175.8M | 151.4M | 147.6M | 149.0M | 123.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −104.2%
- Net margin
- −146.0%
- Return on equity
- 35.1%
- Return on assets
- −78.3%
- Return on capital (ROCE)
- −80.8%
- Liabilities / assets
- 321.9%
- Debt / equity
- —
- Book value / share
- $-10.97
- Revenue growth (YoY)
- 126.3%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -14.22distress
- Accruals / assets
- −30.7%clean
- Beneish M-Score
- 8.13elevated
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 5 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Beneish M-Score elevated — earnings-manipulation screen flag
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
FDA-approved drugs
openFDA · most recent- ATTRUBYNov 22, 2024
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Farallon Capital Partners, L.P.Passive (13G)May 29, 2026
- Janus Henderson Group PlcPassive (13G)May 15, 2026
- Kumar NeilPassive (13G)Apr 16, 2026
- Viking Global Investors LpActivist (13D)Apr 2, 2026
- Vanguard Group IncPassive (13G)Mar 26, 2026
- Price T Rowe Associates Inc /Md/Passive (13G)Nov 14, 2025
- Kkr Genetic Disorder L.P.Activist (13D)May 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 24.2M | 8.7 | +0.6% |
| Apr 30, 2026 | 24.0M | 7.6 | +6.0% |
| Apr 15, 2026 | 22.7M | 13.7 | -3.0% |
| Mar 31, 2026 | 23.4M | 14.7 | -0.6% |
| Mar 13, 2026 | 23.5M | 8.9 | +7.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventMay 27, 2026
- Other material eventMay 13, 2026
- Entered a material agreement · Terminated a material agreementMay 8, 2026
- Results of operations · Other material eventMay 7, 2026
- Other material eventMar 30, 2026
- Results of operationsFeb 24, 2026
- Other material eventFeb 12, 2026
- Entered a material agreement · New financial obligation · Unregistered equity sale · Other material eventJan 21, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13GMay 29, 2026
- 8-KMay 27, 2026
- 4FORM 4May 26, 2026
- 144May 21, 2026
- 4FORM 4May 19, 2026
- 4FORM 4May 19, 2026
- 4FORM 4May 19, 2026
- 4FORM 4May 19, 2026
- 144May 18, 2026
- SCHEDULE 13G/AMay 15, 2026
- 8-KMay 13, 2026
- 4FORM 4May 11, 2026
- 8-KFORM 8-KMay 8, 2026
- S-3ASRMay 8, 2026
- 10-QMay 7, 2026
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.